Case Report: Patient with deficiency of ADA2 presenting leukocytoclastic vasculitis and pericarditis during infliximab treatment
Deficiency of adenosine deaminase 2 (DADA2), first reported in 2014, is a disease with great phenotypic variability, which has been increasingly reported. Therapeutic response depends on the phenotype. We present a case of an adolescent with recurrent fever, oral aphthous ulcers, and lymphadenopathy...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2023-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_ae68f6160c3543dcbe1c84a28a81d5d3 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Diana Simão Raimundo |e author |
| 700 | 1 | 0 | |a Ana Isabel Cordeiro |e author |
| 700 | 1 | 0 | |a João Parente Freixo |e author |
| 700 | 1 | 0 | |a Marta Valente Pinto |e author |
| 700 | 1 | 0 | |a Marta Valente Pinto |e author |
| 700 | 1 | 0 | |a Conceição Neves |e author |
| 700 | 1 | 0 | |a João Farela Neves |e author |
| 700 | 1 | 0 | |a João Farela Neves |e author |
| 700 | 1 | 0 | |a João Farela Neves |e author |
| 245 | 0 | 0 | |a Case Report: Patient with deficiency of ADA2 presenting leukocytoclastic vasculitis and pericarditis during infliximab treatment |
| 260 | |b Frontiers Media S.A., |c 2023-06-01T00:00:00Z. | ||
| 500 | |a 2296-2360 | ||
| 500 | |a 10.3389/fped.2023.1200401 | ||
| 520 | |a Deficiency of adenosine deaminase 2 (DADA2), first reported in 2014, is a disease with great phenotypic variability, which has been increasingly reported. Therapeutic response depends on the phenotype. We present a case of an adolescent with recurrent fever, oral aphthous ulcers, and lymphadenopathy from 8 to 12 years of age and subsequently presented with symptomatic neutropenia. After the diagnosis of DADA2, therapy with infliximab was started, but after the second dose, she developed leukocytoclastic vasculitis and showed symptoms of myopericarditis. Infliximab was switched to etanercept, with no relapses. Despite the safety of tumor necrosis factor alpha inhibitors (TNFi), paradoxical adverse effects have been increasingly reported. The differential diagnosis between disease new-onset manifestations of DADA2 and side effects of TNFi can be challenging and warrants further clarification. | ||
| 546 | |a EN | ||
| 690 | |a DADA2 | ||
| 690 | |a pericarditis | ||
| 690 | |a leukocytoclastic vasculitis | ||
| 690 | |a infliximab | ||
| 690 | |a anti-TNF-α | ||
| 690 | |a adenosine deaminase 2 (ADA2) | ||
| 690 | |a Pediatrics | ||
| 690 | |a RJ1-570 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Frontiers in Pediatrics, Vol 11 (2023) | |
| 787 | 0 | |n https://www.frontiersin.org/articles/10.3389/fped.2023.1200401/full | |
| 787 | 0 | |n https://doaj.org/toc/2296-2360 | |
| 856 | 4 | 1 | |u https://doaj.org/article/ae68f6160c3543dcbe1c84a28a81d5d3 |z Connect to this object online. |